长效吸入剂治疗慢性阻塞性肺疾病临床观察

Clinical Effect of Long-acting Inhalants in Treatment of Chronic Obstructive Pulmonary Disease

目的观察分析长效吸入剂治疗慢性阻塞性肺疾病的临床效果。方法按照随机数表法将2017年1月—2018年7月收治的100例慢性阻塞性肺疾病患者分为A组和B组,每组50例。A组接受LAMA治疗,B组接受ICS/LABA治疗。观察比较两组临床疗效、生活质量及不良反应发生情况。结果 B组治疗总有效率较A组高(96. 00%VS 84. 00%),B组急性加重住院次数、住院总天数均少于A组,差异均有统计学意义(P <0. 05);治疗后两组SGRQ圣乔治评分均较治疗前降低,差异具有统计学意义(P <0. 05); B组患者治疗后SGRQ圣乔治评分较A组低,差异有统计学意义(P <0. 05);两组不良反应发生率相比,差异无统计学意义(P> 0. 05)。结论 ICS/LABA治疗慢性阻塞性肺疾病疗效确切,且不良反应少,有助于改善患者生活质量,值得推广。

Ojbective To analyze the clinical effects of long-acting inhalants in treatment of chronic obstructive pulmonary disease(COPD).Methods A total of 100 COPD patients in the hospital from January 2017 to July 2018 were divided into group A and group B by random number table,with 50 cases in each.Group A was given long-acting muscarinic antagonist(LAMA)therapy,while group B was treated with inhaled corticosteroid/long-actingβ2 adrenergic receptor agonist(ICS/LABA).The clinical efficacy,living quality and adverse reactions were compared between the two groups.Results The total effective rate of group B was higher than that of group A(96.00%vs.84.00%,P<0.05).The number of acute exacerbations and the total number of hospitalizations in group B were lower than those in group A(P<0.05).After treatment,the scores by St.George′s respiratory questionnaire(SGRQ)in the two groups were both significantly decreased compared with those before treatment(P<0.05).After treatment,the SGRQ score in group B was lower than that in group A(P<0.05).There was no statistical difference in the incidence of adverse reactions between the two groups(P>0.05).Conclusion ICS/LABA in the treatment of COPD is effective,and it can improve patients'living quality and have less adverse reactions,so it is worthy of promotion.